If they have finished phase I trials why haven’t they made an announcement? They could at least inform the ASX and shareholders that they are doing the statistical number crunching before officially releasing the results.
The reporter asked if ATH has looked at other applications for PBT 434 with the reply being absolutely. No detail in the response and certainly no mention of PBT2 and it’s usefulness in possible prevention of antibiotic resistance bacteria.
Should not surprise at ATH’s continued lack of respect and information flow for the average shareholder.
Phase1 finished, page-3
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $200 | 66.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 75238609 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 4967441 | 3 |
View Market Depth
| Last trade - 10.00am 10/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |